BioSpaceOriginal article
MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout
Phase 2positiveMapLight schizophrenia candidateCobenfyNeutral
AI Analysis
Summary
MapLight Therapeutics' oral schizophrenia candidate met the primary endpoint in a Phase 2 trial, though analysts expect Bristol Myers Squibb's Cobenfy to maintain its market position despite the mixed readout.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Outcome Details
Reached main endpoint of Phase 2 trial
Importance:5/10
Sentiment:
0.20
schizophreniaoral_candidatePhase_2competitive_landscape
Read the original article
Published by BioSpace on July 27, 2026 3:27 PM